R. Gordon - Oct 16, 2023 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Role: Director, More than 10% owner
Signature: /s/ Christopher Gordon
Stock symbol: CERE
Transactions as of: Oct 16, 2023
Transactions value $: $124,999,986
Form type: 4
Date filed: 10/18/2023, 04:30 PM
Previous filing: Jun 9, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	Price $	Shares After	Date	Ownership	Footnotes
transaction	CERE	Common Stock	+Buy	$124,999,986	+5,480,052	+9.1%	$22.81	65,679,781	Oct 16, 2023	See footnotes	F1, F2
holding	CERE	Common Stock						3,282	Oct 16, 2023	Direct

Explanation of Responses:

Id	Content
F1	Represents shares of the Issuer's common stock held directly by BC Perception Holdings, LP ("BC Perception"). Christopher Gordon is a Partner of Bain Capital Investors, LLC ("BCI"), the ultimate general partner of BC Perception. Voting and investment decisions with respect to securities held by BC Perception are made by the partners of BCI. As a result, Mr. Gordon may be deemed to share voting and dispositive power with respect to the securities held by BC Perception. Mr. Gordon disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.
F2	On October 16, 2023, BC Perception purchased 5,480,052 shares of the Issuer's common stock at a price of $22.81 per share in an underwritten public offering.

Content

Represents shares of the Issuer's common stock held directly by BC Perception Holdings, LP ("BC Perception"). Christopher Gordon is a Partner of Bain Capital Investors, LLC ("BCI"), the ultimate general partner of BC Perception. Voting and investment decisions with respect to securities held by BC Perception are made by the partners of BCI. As a result, Mr. Gordon may be deemed to share voting and dispositive power with respect to the securities held by BC Perception. Mr. Gordon disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.

On October 16, 2023, BC Perception purchased 5,480,052 shares of the Issuer's common stock at a price of $22.81 per share in an underwritten public offering.